#BEGIN_DRUGCARD DB01597

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Primaxin 250 (Cilastatin Sodium + Imipenem)
Primaxin 500 (Cilastatin Sodium + Imipenem)
Primaxin IV 500 (Cilastatin Sodium + Imipenem)

# Brand_Names:
Not Available

# CAS_Registry_Number:
82009-34-5

# ChEBI_ID:
3697

# Chemical_Formula:
C16H26N2O5S

# Chemical_IUPAC_Name:
(2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-{[(1S)-2,2-dimethylcyclopropyl]formamido}hept-2-enoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Protease Inhibitors

# Drug_Interactions:
Cyclosporine	Imipenem increases the effect and toxicity of cyclosporine
Valganciclovir	Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)

# Drug_Reference:
7492120	Keynan S, Hooper NM, Felici A, Amicosante G, Turner AJ: The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cilastatin

# HET_ID:
CIL

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1

# InChI_Key:
InChIKey=DHSUYTOATWAVLW-WFVMDLQDSA-N

# Indication:
Combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect.

# KEGG_Compound_ID:
C01675

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1597

# Mechanism_Of_Action:
Cilastatin is a specific and reversible renal dehydropeptidase-I inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to block the metabolism and thus the inactivation of imipenem so that antibacterial levels of imipenem can be attained in the urine. The drug also prevents the metabolism of leukotriene D4 to leukotriene E4 through the inhibition of leukotriene D4 dipeptidase.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
358.453

# Molecular_Weight_Mono:
358.156242642

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1ITU

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448998

# Pharmacology:
Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin is therefore combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect. However, cilastatin in and of itself does not have any antibacterial activity.

# Predicted_LogP_Hydrophobicity:
-0.29

# Predicted_LogS:
-3.5

# Predicted_Water_Solubility:
1.00e-01 g/l

# Primary_Accession_No:
DB01597

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6435415

# PubChem_Substance_ID:
46505611

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00918

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](CSCCCC\C=C(/NC(=O)[C@H]1CC1(C)C)C(=O)O)C(=O)O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:18 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cilastatin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane
GPI-anchor. Note=Brush border membrane
apical cell membrane
lipid- anchor

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2571484	Lin JH, Chen IW, Ulm EH: Dose-dependent kinetics of cilastatin in laboratory animals. Drug Metab Dispos. 1989 Jul-Aug;17(4):426-32.
3038022	Farrell CA, Allegretto NJ, Hitchcock MJ: Cilastatin-sensitive dehydropeptidase I enzymes from three sources all catalyze carbapenem hydrolysis and conversion of leukotriene D4 to leukotriene E4. Arch Biochem Biophys. 1987 Jul;256(1):253-9.
3474745	Hirota T, Nishikawa Y, Komai T, Igarashi T, Kitagawa H: Role of dehydropeptidase-I in the metabolism of glutathione and its conjugates in the rat kidney. Res Commun Chem Pathol Pharmacol. 1987 May;56(2):235-42.
3480361	Kumon H, Nasu Y, Ohmori H, Kodama H, Konishi Y: [Effects of cilastatin sodium, an inhibitor of dehydropeptidase-I, on human urinary peptide excretion. Patients with renal insufficiency] Jpn J Antibiot. 1987 Sep;40(9):1571-83.
3780719	Hirota T, Nishikawa Y, Tanaka M, Igarashi T, Kitagawa H: Characterization of dehydropeptidase I in the rat lung. Eur J Biochem. 1986 Nov 3;160(3):521-5.
7492120	Keynan S, Hooper NM, Felici A, Amicosante G, Turner AJ: The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31.
9573653	Richerson MA, Ambrose PG, Quintiliani R, Nightingale CH: Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. Conn Med. 1998 Mar;62(3):165-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
DPEP1

# Drug_Target_1_GenBank_ID_Gene:
D13137

# Drug_Target_1_GenBank_ID_Protein:
219600

# Drug_Target_1_GeneCard_ID:
DPEP1

# Drug_Target_1_Gene_Name:
DPEP1

# Drug_Target_1_Gene_Sequence:
>1236 bp
ATGTGGAGCGGATGGTGGCTGTGGTCCCTTGTGGCCGTCTGCACTGCAGACTTCTTTCGG
GACGAGGCAGAGAGGATCATGAGGGACTCCCCTGTCATTGATGGGCACAATGACCTCCCC
TGGCAGCTGCTGGATATGTTCAACAACCGGCTGCAGGACGAGAGGGCCAACCTGACCACC
TTGGCCGGCACACACACCAACATCCCCAAGCTGAGGGCCGGCTTTGTGGGAGGCCAGTTC
TGGTCCGTGTACACGCCCTGCGACACCCAGAACAAAGACGCCGTGCGGAGGACGCTGGAG
CAGATGGACGTGGTCCACCGCATGTGCCGGATGTACCCGGAGACCTTCCTGTATGTCACC
AGCAGTGCAGGCATTCGGCAGGCCTTCCGGGAAGGGAAGGTGGCCAGCCTGATCGGCGTG
GAGGGCGGCCACTCCATTGACAGCAGTTTGGGCGTCCTGCGGGCACTCTATCAGCTGGGC
ATGCGGTACCTGACCCTCACCCACAGCTGCAACACGCCCTGGGCTGACAACTGGCTGGTG
GACACGGGAGACAGCGAGCCCCAGAGCCAAGGCTTGTCACCCTTTGGGCAGCGTGTGGTG
AAGGAGCTGAACCGTCTGGGGGTCCTCATCGACTTGGCTCACGTGTCTGTGGCCACCATG
AAGGCCACCCTGCAGCTGTCCAGAGCCCCGGTCATCTTCAGCCACTCCTCGGCCTACAGC
GTGTGCGCAAGCCGGCGCAACGTGCCTGACGACGTCCTGAGGCTGGTGAAACAGACAGAC
AGCCTGGTGATGGTGAACTTCTACAACAATTACATTTCCTGCACCAACAAGGCCAACCTG
TCCCAAGTGGCCGACCATCTGGATCACATCAAGGAGGTGGCAGGAGCCAGAGCCGTGGGT
TTTGGTGGGGACTTTGATGGTGTTCCAAGGGTCCCTGAGGGGCTGGAGGACGTCTCCAAG
TATCCAGACCTGATCGCTGAGCTGCTCAGGAGGAACTGGACGGAGGCGGAGGTCAAGGGC
GCACTGGCTGACAACCTGCTGAGGGTCTTCGAGGCTGTGGAACAGGCCAGCAACCTCACA
CAGGCTCCCGAGGAGGAGCCCATCCCGCTGGACCAGCTGGGTGGCTCCTGCAGGACCCAT
TACGGCTACTCCTCTGGGGCTTCCAGCCTCCATCGCCACTGGGGGCTCCTGCTGGCCTCC
CTCGCTCCCCTGGTCCTCTGTCTGTCTCTCCTGTGA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
12144777	Nitanai Y, Satow Y, Adachi H, Tsujimoto M: Crystal structure of human renal dipeptidase involved in beta-lactam hydrolysis. J Mol Biol. 2002 Aug 9;321(2):177-84.
2137335	Hooper NM, Keen JN, Turner AJ: Characterization of the glycosyl-phosphatidylinositol-anchored human renal dipeptidase reveals that it is more extensively glycosylated than the pig enzyme. Biochem J. 1990 Jan 15;265(2):429-33.
2168407	Adachi H, Katayama T, Inuzuka C, Oikawa S, Tsujimoto M, Nakazato H: Identification of membrane anchoring site of human renal dipeptidase and construction and expression of a cDNA for its secretory form. J Biol Chem. 1990 Sep 5;265(25):15341-5.
2303490	Adachi H, Tawaragi Y, Inuzuka C, Kubota I, Tsujimoto M, Nishihara T, Nakazato H: Primary structure of human microsomal dipeptidase deduced from molecular cloning. J Biol Chem. 1990 Mar 5;265(7):3992-5.
2768222	Adachi H, Kubota I, Okamura N, Iwata H, Tsujimoto M, Nakazato H, Nishihara T, Noguchi T: Purification and characterization of human microsomal dipeptidase. J Biochem (Tokyo). 1989 Jun;105(6):957-61.
7764673	Satoh S, Ohtsuka K, Keida Y, Kusunoki C, Konta Y, Niwa M, Kohsaka M: Gene structural analysis and expression of human renal dipeptidase. Biotechnol Prog. 1994 Mar-Apr;10(2):134-40.
8097406	Adachi H, Katayama T, Nakazato H, Tsujimoto M: Importance of Glu-125 in the catalytic activity of human renal dipeptidase. Biochim Biophys Acta. 1993 Apr 21;1163(1):42-8.
8439558	Satoh S, Kusunoki C, Konta Y, Niwa M, Kohsaka M: Cloning and structural analysis of genomic DNA for human renal dipeptidase. Biochim Biophys Acta. 1993 Feb 20;1172(1-2):181-3.

# Drug_Target_1_HGNC_ID:
HGNC:3002

# Drug_Target_1_HPRD_ID:
01563

# Drug_Target_1_ID:
2016

# Drug_Target_1_Locus:
16q24.3

# Drug_Target_1_Molecular_Weight:
45674

# Drug_Target_1_Name:
Dipeptidase 1

# Drug_Target_1_Number_of_Residues:
411

# Drug_Target_1_PDB_ID:
1ITU

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01244	Peptidase_M19

# Drug_Target_1_Protein_Sequence:
>Dipeptidase 1 precursor
MWSGWWLWPLVAVCTADFFRDEAERIMRDSPVIDGHNDLPWQLLDMFNNRLQDERANLTT
LAGTHTNIPKLRAGFVGGQFWSVYTPCDTQNKDAVRRTLEQMDVVHRMCRMYPETFLYVT
SSAGIRQAFREGKVASLIGVEGGHSIDSSLGVLRALYQLGMRYLTLTHSCNTPWADNWLV
DTGDSEPQSQGLSPFGQRVVKELNRLGVLIDLAHVSVATMKATLQLSRAPVIFSHSSAYS
VCASRRNVPDDVLRLVKQTDSLVMVNFYNNYISCTNKANLSQVADHLDHIKEVAGARAVG
FGGDFDGVPRVPEGLEDVSKYPDLIAELLRRNWTEAEVKGALADNLLRVFEAVEQASNLT
QAPEEEPIPLDQLGGSCRTHYGYSSGASSLHRHWGLLLASLAPLVLCLSLL

# Drug_Target_1_Reaction:
Hydrolysis of dipeptides COFACTOR Zinc INHIBITOR Cilastatin

# Drug_Target_1_Signals:
1-16

# Drug_Target_1_Specific_Function:
Hydrolyzes a wide range of dipeptides. Implicated in the renal metabolism of glutathione and its conjugates. Converts leukotriene D4 to leukotriene E4; it may play an important role in the regulation of leukotriene activity

# Drug_Target_1_SwissProt_ID:
P16444

# Drug_Target_1_SwissProt_Name:
DPEP1_HUMAN

# Drug_Target_1_Synonyms:
Dehydropeptidase-I
Dipeptidase 1 precursor
EC 3.4.13.19
Microsomal dipeptidase
Renal dipeptidase
hRDP

# Drug_Target_1_Theoretical_pI:
6.09

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01597
